BioNTech SE (NASDAQ:BNTX) Stake Boosted by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of BioNTech SE (NASDAQ:BNTXGet Rating) by 38.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,499 shares of the company’s stock after purchasing an additional 415 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in BioNTech were worth $224,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Flossbach Von Storch AG acquired a new stake in BioNTech during the first quarter worth about $327,490,000. Quinn Opportunity Partners LLC raised its stake in BioNTech by 603.3% during the 1st quarter. Quinn Opportunity Partners LLC now owns 402,239 shares of the company’s stock worth $68,606,000 after buying an additional 345,049 shares during the period. BlackRock Inc. grew its stake in BioNTech by 25.9% in the first quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock valued at $274,768,000 after acquiring an additional 331,101 shares during the period. Renaissance Technologies LLC bought a new stake in BioNTech during the 1st quarter worth approximately $42,711,000. Finally, First Trust Advisors LP boosted its stake in BioNTech by 62.0% in the 1st quarter. First Trust Advisors LP now owns 489,951 shares of the company’s stock worth $83,566,000 after purchasing an additional 187,569 shares during the period. 13.77% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Up 6.2 %

Shares of NASDAQ BNTX opened at $154.31 on Monday. The company has a current ratio of 5.15, a quick ratio of 5.06 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $37.45 billion, a PE ratio of 2.98 and a beta of 0.12. The firm has a fifty day simple moving average of $138.19 and a two-hundred day simple moving average of $148.20. BioNTech SE has a 12 month low of $117.08 and a 12 month high of $374.58.

BioNTech (NASDAQ:BNTXGet Rating) last released its earnings results on Monday, August 8th. The company reported $7.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.69 by ($0.38). The business had revenue of $3.20 billion for the quarter, compared to analyst estimates of $4.11 billion. BioNTech had a return on equity of 88.76% and a net margin of 55.43%. BioNTech’s quarterly revenue was down 39.8% compared to the same quarter last year. During the same quarter last year, the company earned $12.98 earnings per share. Equities analysts expect that BioNTech SE will post 32.49 earnings per share for the current year.

Wall Street Analyst Weigh In

BNTX has been the topic of a number of recent research reports. Morgan Stanley lowered their target price on BioNTech from $195.00 to $194.00 and set an “equal weight” rating on the stock in a research report on Friday, July 15th. SVB Leerink increased their price target on shares of BioNTech from $223.00 to $224.00 and gave the company an “outperform” rating in a report on Friday, July 29th. HC Wainwright decreased their target price on BioNTech from $283.00 to $272.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th. Cowen started coverage on BioNTech in a report on Wednesday, August 17th. They set a “market perform” rating for the company. Finally, Deutsche Bank Aktiengesellschaft set a $180.00 price objective on BioNTech in a research report on Thursday, September 8th. Seven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech presently has a consensus rating of “Hold” and an average target price of $217.69.

BioNTech Company Profile

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Featured Articles

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTXGet Rating).

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.